Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma
Multiple myeloma (MM) is an aggressive and incurable disease for most patients, characterized by periods of treatment, remission and relapse. The introduction of new classes of drugs, such as proteasome inhibitors (PIs), has improved survival outcomes in these patient populations. The proteasome is...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/28/3/1438 |
| _version_ | 1827759799180197888 |
|---|---|
| author | Francesca Alessandra Ambrosio Giosuè Costa Maria Eugenia Gallo Cantafio Roberta Torcasio Francesco Trapasso Stefano Alcaro Giuseppe Viglietto Nicola Amodio |
| author_facet | Francesca Alessandra Ambrosio Giosuè Costa Maria Eugenia Gallo Cantafio Roberta Torcasio Francesco Trapasso Stefano Alcaro Giuseppe Viglietto Nicola Amodio |
| author_sort | Francesca Alessandra Ambrosio |
| collection | DOAJ |
| description | Multiple myeloma (MM) is an aggressive and incurable disease for most patients, characterized by periods of treatment, remission and relapse. The introduction of new classes of drugs, such as proteasome inhibitors (PIs), has improved survival outcomes in these patient populations. The proteasome is the core of the ubiquitin–proteasome system (UPS), a complex and conserved pathway involved in the control of multiple cellular processes, including cell cycle control, transcription, DNA damage repair, protein quality control and antigen presentation. To date, PIs represent the gold standard for the treatment of MM. Bortezomib was the first PI approved by the FDA, followed by next generation of PIs, namely carfilzomib and ixazomib. Natural agents play an important role in anti-tumor drug discovery, and many of them have recently been reported to inhibit the proteasome, thus representing a new potential source of anti-MM drugs. Based on the pivotal biological role of the proteasome and on PIs’ significance in the management of MM, in this review we aim to briefly summarize recent evidence on natural compounds capable of inhibiting the proteasome, thus triggering anti-MM activity. |
| first_indexed | 2024-03-11T09:32:40Z |
| format | Article |
| id | doaj.art-b4052deb237d4897a3d3dfb61e1d44c3 |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-11T09:32:40Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-b4052deb237d4897a3d3dfb61e1d44c32023-11-16T17:32:28ZengMDPI AGMolecules1420-30492023-02-01283143810.3390/molecules28031438Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple MyelomaFrancesca Alessandra Ambrosio0Giosuè Costa1Maria Eugenia Gallo Cantafio2Roberta Torcasio3Francesco Trapasso4Stefano Alcaro5Giuseppe Viglietto6Nicola Amodio7Department of Experimental and Clinical Medicine, Campus “S. Venuta”, University “Magna Græcia” of Catanzaro, Viale Europa, 88100 Catanzaro, ItalyDepartment of Health Sciences, University “Magna Græcia” of Catanzaro, Campus “S. Venuta”, Viale Europa, 88100 Catanzaro, ItalyDepartment of Experimental and Clinical Medicine, Campus “S. Venuta”, University “Magna Græcia” of Catanzaro, Viale Europa, 88100 Catanzaro, ItalyDepartment of Experimental and Clinical Medicine, Campus “S. Venuta”, University “Magna Græcia” of Catanzaro, Viale Europa, 88100 Catanzaro, ItalyDepartment of Experimental and Clinical Medicine, Campus “S. Venuta”, University “Magna Græcia” of Catanzaro, Viale Europa, 88100 Catanzaro, ItalyDepartment of Health Sciences, University “Magna Græcia” of Catanzaro, Campus “S. Venuta”, Viale Europa, 88100 Catanzaro, ItalyDepartment of Experimental and Clinical Medicine, Campus “S. Venuta”, University “Magna Græcia” of Catanzaro, Viale Europa, 88100 Catanzaro, ItalyDepartment of Experimental and Clinical Medicine, Campus “S. Venuta”, University “Magna Græcia” of Catanzaro, Viale Europa, 88100 Catanzaro, ItalyMultiple myeloma (MM) is an aggressive and incurable disease for most patients, characterized by periods of treatment, remission and relapse. The introduction of new classes of drugs, such as proteasome inhibitors (PIs), has improved survival outcomes in these patient populations. The proteasome is the core of the ubiquitin–proteasome system (UPS), a complex and conserved pathway involved in the control of multiple cellular processes, including cell cycle control, transcription, DNA damage repair, protein quality control and antigen presentation. To date, PIs represent the gold standard for the treatment of MM. Bortezomib was the first PI approved by the FDA, followed by next generation of PIs, namely carfilzomib and ixazomib. Natural agents play an important role in anti-tumor drug discovery, and many of them have recently been reported to inhibit the proteasome, thus representing a new potential source of anti-MM drugs. Based on the pivotal biological role of the proteasome and on PIs’ significance in the management of MM, in this review we aim to briefly summarize recent evidence on natural compounds capable of inhibiting the proteasome, thus triggering anti-MM activity.https://www.mdpi.com/1420-3049/28/3/1438proteasomenatural compoundsproteasome inhibitorsmultiple myeloma |
| spellingShingle | Francesca Alessandra Ambrosio Giosuè Costa Maria Eugenia Gallo Cantafio Roberta Torcasio Francesco Trapasso Stefano Alcaro Giuseppe Viglietto Nicola Amodio Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma Molecules proteasome natural compounds proteasome inhibitors multiple myeloma |
| title | Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma |
| title_full | Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma |
| title_fullStr | Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma |
| title_full_unstemmed | Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma |
| title_short | Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma |
| title_sort | natural agents as novel potential source of proteasome inhibitors with anti tumor activity focus on multiple myeloma |
| topic | proteasome natural compounds proteasome inhibitors multiple myeloma |
| url | https://www.mdpi.com/1420-3049/28/3/1438 |
| work_keys_str_mv | AT francescaalessandraambrosio naturalagentsasnovelpotentialsourceofproteasomeinhibitorswithantitumoractivityfocusonmultiplemyeloma AT giosuecosta naturalagentsasnovelpotentialsourceofproteasomeinhibitorswithantitumoractivityfocusonmultiplemyeloma AT mariaeugeniagallocantafio naturalagentsasnovelpotentialsourceofproteasomeinhibitorswithantitumoractivityfocusonmultiplemyeloma AT robertatorcasio naturalagentsasnovelpotentialsourceofproteasomeinhibitorswithantitumoractivityfocusonmultiplemyeloma AT francescotrapasso naturalagentsasnovelpotentialsourceofproteasomeinhibitorswithantitumoractivityfocusonmultiplemyeloma AT stefanoalcaro naturalagentsasnovelpotentialsourceofproteasomeinhibitorswithantitumoractivityfocusonmultiplemyeloma AT giuseppeviglietto naturalagentsasnovelpotentialsourceofproteasomeinhibitorswithantitumoractivityfocusonmultiplemyeloma AT nicolaamodio naturalagentsasnovelpotentialsourceofproteasomeinhibitorswithantitumoractivityfocusonmultiplemyeloma |